Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.

Dimitrios BasoulisElpida MastrogianniGeorgios Karamanakos Aikaterini Gkoufa Vasiliki Epameinondas GeorgakopoulouSotiria MakrodimitriMaria N GamaletsouAntonios MarkogiannakisNikolaos V Sipsas

Published in: Viruses (2024)

TXG/CIL provides effective prophylaxis against COVID-19 in immunocompromised patients. Future strategies should focus on developing new mAb combinations to address emerging SARS-CoV-2 variants and protect vulnerable populations.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
chronic kidney disease
respiratory syndrome coronavirus
prognostic factors
peritoneal dialysis
patient reported outcomes
early onset
intensive care unit
copy number
patient reported